SCHEMBL4616150

SCHEMBL4616150

CCc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)N1CCN(CCCN2CCOCC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
SFRP1 Q8N474 2/20 0.58
LMNA P02545 3/20 0.47
TSHR P16473 3/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RECQL P46063 1/20 0.42
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616470 0.97 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4617036 0.89 SFRP1 (0.64) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4616587 0.88 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4615604 0.85 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4616398 0.84 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL4618864 0.82 SFRP1 (0.53) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4616479 0.80 SFRP1 (0.74) ALDH1A1SMN1; SMN2L3MBTL1SFRP1TSHR
SCHEMBL4619173 0.77 L3MBTL1 (0.54) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4617911 0.77 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2L3MBTL1SFRP1LMNA
SCHEMBL4618852 0.73 SFRP1 (1.00) ALDH1A1L3MBTL1SFRP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 ALDH1A1 1865/4885SMN1; SMN2 2404/4885L3MBTL1 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.